Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Medtronic
Baxter
Colorcon
Mallinckrodt

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for RRx-001

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug RRx-001: Sponsors, patents, clinical trial progress

RRx-001 is an investigational drug.

There have been 11 clinical trials for RRx-001. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2018.

The most common disease conditions in clinical trials are Lymphoma, Carcinoma, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are EpicentRx, Inc., Drais Pharmaceuticals, Inc., and [disabled in preview].

There are seven US patents protecting this investigational drug and thirty-eight international patents.

Recent Clinical Trials for RRx-001
TitleSponsorPhase
RRx-001 Prior to a Platinum Doublet or a Platinum Doublet Alone in Patients With Small Cell CarcinomaEpicentRx, Inc.Phase 3
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral CancersDrais Pharmaceuticals, Inc.Phase 2
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral CancersEpicentRx, Inc.Phase 2

See all RRx-001 clinical trials

Clinical Trial Summary for RRx-001

Top disease conditions for RRx-001
Top clinical trial sponsors for RRx-001

See all RRx-001 clinical trials

US Patents for RRx-001

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
RRx-001   See Pricing Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof RadioRx, Inc. (Menlo Park, CA) Alliant Techsystems Inc. (Edina, MN)   See Pricing
RRx-001   See Pricing Methods of synthesizing cyclic nitro compounds Alliant Techsystems Inc. (Minneapolis, MN)   See Pricing
RRx-001   See Pricing Methods of synthesizing cyclic nitro compounds Alliant Techsystems Inc. (Arlington, VA)   See Pricing
RRx-001   See Pricing Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof RadioRx, Inc. (Menlo Park, CA) Alliant Techsystems Inc. (Minneapolis, MN)   See Pricing
RRx-001   See Pricing Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same Alliant Techsystems Inc. (Arlington, VA)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for RRx-001

Drugname Country Document Number Estimated Expiration Related US Patent
RRx-001 Australia 2006279589 2025-08-12   See Pricing
RRx-001 Canada 2620612 2025-08-12   See Pricing
RRx-001 China 101370492 2025-08-12   See Pricing
RRx-001 Cyprus 1116094 2025-08-12   See Pricing
RRx-001 Denmark 1924253 2025-08-12   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Johnson and Johnson
Moodys
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.